Blog
RSS FeedPosted by Michael Wonder on 04 Oct 2018
ICER final report highlights uncertainty in long-term safety and effectiveness of new treatments for hereditary transthyretin amyloidosis, discusses options for insurance coverage criteria
4 October 2018 - The ICER today released a final evidence report and report-at-a-glance on inotersen (Akcea Therapeutics) and patisiran ...
Posted by Michael Wonder on 04 Oct 2018
ICER review highlights the clinical benefits of using anti-androgen therapies to treat earlier stage prostate cancer
4 October 2018 - Midwest CEPAC’s vote on value reflects uncertainty around duration of treatment with anti-androgens. ...
Posted by Michael Wonder on 27 Sep 2018
Paying for value: US state of play
27 September 2018 - Drug pricing in the US is a perennial topic, which is no surprise given the the ...
Posted by Michael Wonder on 25 Sep 2018
ICER releases draft evidence report on biologic treatments for asthma
24 September 2018 - Public comment period now open until 22 October 2018; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 20 Sep 2018
Will CVS Caremark make ICER the American NICE?
20 September 2018 - Rationing of some sort is part and parcel of every healthcare system. Simply put, it refers to ...
Posted by Michael Wonder on 07 Sep 2018
ICER releases draft evidence report on medications for treatment of opioid use disorder
7 September 2018 - Public comment period now open until 4 October 2018; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 30 Aug 2018
ICER finds current list price of patisiran for amyloidosis far exceeds standard cost-effectiveness levels
29 August 2018 - Report also evaluates evidence on inotersen; during public meeting of Midwest CEPAC on 13 September, a policy ...
Posted by Michael Wonder on 25 Aug 2018
This drug is safe and effective. Wait. Compared with what?
20 August 2018 - Comparative effectiveness research may be the best way to answer questions that patients and physicians face every ...
Posted by Michael Wonder on 25 Aug 2018
ICER report finds evidence inadequate to distinguish the clinical benefits of different anti-androgen therapies for men with non-metastatic castration-resistant prostate cancer
24 August 2018 - Added costs of treating earlier stage disease with all therapies are aligned with their added clinical benefits ...
Posted by Michael Wonder on 23 Aug 2018
ICER releases draft evidence report on long-term treatments for prevention of hereditary angioedema attacks
23 August 2018 - Public comment period now open until 20 September; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 22 Aug 2018
ICER posts draft scoping document on AVXS-101 and nusinersen for spinal muscular atrophy
22 August 2018 - Document open to public comment until 7 September 2018. ...
Posted by Michael Wonder on 04 Aug 2018
ICER final report highlights limitations in evidence on long-term safety and effectiveness of elagolix for endometriosis, discusses options for insurance coverage criteria
3 August 2018 - Because elagolix’s price aligns with clinical benefit only when compared to no other treatment, insurers may first ...
Posted by Michael Wonder on 04 Aug 2018
ICER updated report on targeted treatments for plaque psoriasis finds guselkumab and risankizumab offer superior health benefit compared with TNFα inhibitors
3 August 2018 - Policy recommendations repeat call for insurers to minimise step therapy requirements on these treatments that are priced ...
Posted by Michael Wonder on 02 Aug 2018
Institute for Clinical and Economic Review lists potential options for assessments in 2019
2 August 2018 - ICER will select 2019 topics from a wide range of treatments, medical devices, and IT-based interventions. ...
Posted by Michael Wonder on 01 Aug 2018
Institute for Clinical and Economic Review posts draft scoping document on canakinumab for atherosclerosis
1 August 2018 - Document open to public comment until August 22, 2018. ...